## Reduction in Urinary and Blood Biomarkers of Tobacco Exposure in Smokers Switched to an ENDS Product

CORESTA

19 Oct 2022

Milly Kanobe, Bobbette Jones, Peter Chen, Eckhardt Schmidt, John Darnell, Buddy Brown



Reynolds American Inc. and its affiliates are independent subsidiaries of the British American Tobacco Group

### Background



Biomarkers of exposure (BoE) can help evaluate exposure to combustion-related, tobacco-specific toxicants after smokers switch from cigarettes to potentially less-harmful products like ENDS.

Three Vuse ENDS products were evaluated in this study: Vuse Vibe, Vuse Solo, and Vuse Ciro, all in Original (tobacco) flavor.

All evaluated products received Marketing Granted Orders by FDA Center for Tobacco Products in October 2021 (Vuse Solo) and Vuse Ciro and Vuse Vibe (May 2022).



### **Clinical Study Objectives**





### **BoE Endpoints**



Biomarker	Associated Toxicant	Chemical Classification
Urinary BoE		
<ul> <li>1-AN</li> <li>2-AN</li> <li>4-ABP</li> <li>o-Tol</li> </ul>	<ul> <li>1-aminonaphthalene<sup>1</sup></li> <li>2-aminonaphthalene<sup>1</sup></li> <li>4-aminobiphenyl<sup>1</sup></li> <li>o-toluidine<sup>2</sup></li> </ul>	Aromatic Amines
<ul> <li>CEMA</li> <li>HMPMA</li> <li>HPMA</li> <li>MHBMA</li> <li>SPMA</li> </ul>	<ul> <li>Acrylonitrile<sup>1</sup></li> <li>Crotonaldehyde<sup>1</sup></li> <li>Acrolein<sup>1</sup></li> <li>1,3-butadiene<sup>1</sup></li> <li>Benzene<sup>1</sup></li> </ul>	Semi-volatile Organics (Mercapturic Acids)
• 3-OH-B[a]P)	B[a]P <sup>1</sup>	Polycyclic Aromatic Hydrocarbon
NNAL     NNN	• NNK <sup>1</sup> • NNN <sup>1</sup>	Tobacco-specific Nitrosamines
Unconjugated nicotine	Nicotine+5 metabolites	Total Nicotine Equivalents
Blood BoE		
Carboxyhemoglobin	Carbon monoxide <sup>2</sup>	

<sup>1</sup>Constituent included in FDA HPHC list (<u>Federal Register, 2012</u>) and the PMTA ENDS Draft/Final Guidance (<u>FDA, 2016/2019</u>). <sup>2</sup>Constituent included in FDA list of HPHCs in Tobacco Products and Tobacco Smoke (<u>Federal Register, 2012</u>).

### **Clinical Study Design**



	B	In-Clinic Confinement Baseline Post-Product Switch					-		‡	
Screening Visit				Vibe						
	Usual Combi	Usual Brand Combustible Cigarette (Non-menthol)	Solo					· •		
	Cigare (Non-n		Ciro					• • • • • •		
				Abstinence					····•	
	Day -2	Day -1	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8
Enrollment	-									
Randomiza	ition		•							
8h Food an	d Nicotine Fast	<b></b>				-	-	•		
24h Urine C	Collection (BOE	)	-					i i		<b></b> _
Blood Sam	ples (Nic/Cot)									
Blood Sam	ples (BOE)	-	-		-		•			
Discharge										•



### **Smokers of non-menthol cigarettes**

Cohort	Randomized	Completed
Vibe	37	33
Solo	35	35
Ciro	37	35
Abstinence	16	11
Total	125	114

# **Study Results**

3 # VUSE VIBE VAPOR PEN Original Kit	4.8 %	CIRO VAPORE-CIG
VAPOR PRODUCTS	2 Cartridges	VAPOR PRODUCTS
WARNING: This product contains nicotine. Nicotine is an addictive chemical.	This product contains nicotine. Nicotine is an addictive chemical.	WARNING: This product contains nicotine. Nicotine is an addictive chemical.



### **Subject Demographics**





#### **Urinary BoE: Aromatic Amines**





\*p<0.05 Bonferroni-adjusted

#### **Urinary BoE: Mercapturic Acids**





\*p<0.05 Bonferroni-adjusted



BoE to mercapturic acids were significantly reduced in all product-switch cohorts.

Similar reductions were observed in the Abstinence cohort.

# Urinary BoE: 3-OH-B[a]P, TSNAs and Total Nicotine Equivalents



\*p<0.05 Bonferroni-adjusted; ns = not significant

#### **RESULTS:**

BEYN

A BETTER TOMORR

BoE to B[a]P, NNK, and NNN were significantly reduced in all productswitch cohorts.

Significant reductions in TNEq. were observed for subjects in Vuse Solo and Vuse Ciro Cohorts.

Reductions in product-switch cohorts were similar to those observed in Abstinence. 2022\_ST09

One subject in Abstinence cohort with an extreme data value at baseline was excluded from Total NNN analysis.

#### **Blood BoE: Carboxyhemoglobin**





#### **RESULTS:**

BoE to carbon monoxide were significantly reduced post-product switch in all Vuse ENDS and Abstinence Cohorts.

#### **Daily ENDS Product Use**





2022\_ST09\_Kanobe.pd

### Summary





#### **Overall Conclusions**



2022\_ST09\_Kan

For Vuse ENDS users, the exposure to tobacco smoke toxicants was significantly reduced to comparable magnitudes as abstinence from smoking.

The data collected in this study add to the body of evidence supporting that ENDS pose less individual risk to tobacco product consumers than combustible cigarettes.



#### Contract Research Organization

Vince & Associates Clinical Research Inc. Overland Park, KS

#### Study Sites

Vince & Associates Clinical Research Inc. Overland Park, KS

DaVita Clinical Research Minneapolis, MN

#### Bioanalytical Laboratory

Analytisch-Biologisches Forschungslabor GmbH (ABF), Planegg, Germany

RAIS Colleagues

Clinical Studies Division Submissions

Audience for listening

# **Thank You!**

# **Questions?**



ess2022 - Document not peer-reviewed by CORES